This comparison is really about two philosophies of where evidence should live. Heidi has grown from ambient documentation into an integrated clinical-workflow product, with Heidi Evidence providing cited clinical answers in proximity to the consultation, the note and the follow-up, the pitch being continuity: the question asked where the care happens. iatroX is a dedicated clinical knowledge, reasoning and learning platform: Ask-iatroX for source-grounded UK answers, medicines pages with SmPC links, calculators, question banks, Socratic tutoring and CPD, the pitch being depth: a layer built entirely around evidence, verification and learning. Both descriptions are public and current at writing, and the useful comparison walks a whole consultation rather than a feature grid.
The consultation walkthrough
History captured: the scribe's home ground, and a documentation function iatroX does not offer and should not pretend to; an ANP using ambient capture uses Heidi or another locally approved scribe, full stop. Note generated: same territory, with the standing rule that generated notes are drafts the clinician verifies, medicine names, doses and allergies especially, before anything downstream inherits them. Clinical uncertainty identified: the fork in the comparison, because the question "what should I do about this finding?" can now be asked inside the integrated product or in a dedicated evidence layer, and the difference is what sits behind the answer. Evidence question asked: the dedicated layer's case is architectural, UK-first retrieval across NICE, CKS, SIGN and MHRA, relevant SmPCs surfaced, research reachable, and every claim one click from its source, the inspection standard this cluster measures everything against. Medicine checked: product-level verification ends at the exact SmPC on emc whichever tool started the journey, and the medicines-navigation layer exists to make that journey two clicks. Safety-netting drafted: either system can draft; the clinician's review against the PIL and local pathway is the safety step. Learning logged: the dedicated platform's distinctive close, the question, sources, reflection and competency mapping retained as portfolio evidence, the loop a documentation-first product has no reason to build.
The integration question, handled without marketing physics
The tempting inference, evidence embedded in the workflow must be safer because it is fewer clicks away, deserves direct treatment: integration reduces friction, and friction reduction cuts both ways, because the same proximity that makes asking easier makes accepting easier, and automation bias grows exactly where verification costs feel highest relative to the flow. Fewer clicks to an answer is a genuine benefit; fewer clicks to an inspected source is the benefit that matters, and the honest test for any embedded evidence function is the same one this cluster applies everywhere: from the answer, how far is the exact supporting passage, and does the workflow make opening it feel like part of the job or an interruption to it? A prescriber can get this right in either architecture and wrong in either; the architecture just changes which failure is being resisted.
The verdict, which is a configuration
The likely right answer for most ANPs is complementary: Heidi or another approved scribe for consultation capture and documentation, where integration is pure gain; iatroX as the knowledge and verification layer for evidence interrogation, medicines checking against SmPCs, calculators and the learning record, where dedication is the gain. The configuration keeps the two risk chains separate by design: transcription errors stay in a document the clinician reviews, and evidence questions get asked cleanly rather than inherited from a transcript, the separation argued in full in the scribes-versus-evidence analysis this cluster includes. What the verdict refuses is the collapsed version, any single product treated as consultation, note, evidence and decision in one motion, because each join in that chain is where the checking lives, and the checking is the job.
Frequently asked questions
Is running two products realistic under clinic time pressure?
The division costs seconds and buys separation: the scribe runs ambiently, the evidence question is one deliberate ask, and the alternative, evidence inherited unexamined from workflow momentum, is the expensive option wearing efficiency's badge.
What should institutional buyers make of this comparison?
That it is two procurements, not one: documentation tools and evidence layers have different governance profiles, data flows and failure modes, and the twelve-item vendor rubric applies to each separately.
Could the two categories merge well eventually?
They may, and the standard travels with them: whoever builds the merged product inherits the inspection test, exact sources one honest click away, with the automation-bias pressure of integration engineered against rather than marketed as seamlessness.
Which product should a lone ANP in a small practice prioritise first?
By binding constraint, as ever: drowning in documentation, the scribe first; drowning in clinical uncertainty and CPD debt, the knowledge layer first; the configuration argument only says do not expect either purchase to perform the other's job.